Focused On-demand Library for Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit DAD1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P61803

UPID:

DAD1_HUMAN

Alternative names:

Defender against cell death 1

Alternative UPACC:

P61803; D3DS25; O08552; O70364; P46966; P46968; Q6FGA3; Q96GB7

Background:

Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit DAD1, also known as Defender against cell death 1, plays a crucial role in protein N-glycosylation. This process involves the transfer of a specific glycan from dolichol-pyrophosphate to an asparagine residue within nascent polypeptide chains, a fundamental step in protein maturation and function. DAD1 is a vital component of the oligosaccharyl transferase (OST) complex, working in concert with the Sec61 complex to facilitate protein translocation across the endoplasmic reticulum.

Therapeutic significance:

Understanding the role of Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit DAD1 could open doors to potential therapeutic strategies.